Key Takeaways
- • Onco3R Therapeutics, a Belgian biotech founded in 2025 to acquire distressed assets from Galapagos Pharmaceuticals, has secured $125 million in Series A funding and is rebranding as Coultreon Biopharma.
- • The funding validates a strategy of acquiring rescued drug candidates and development programs from a larger biotech firm facing financial or strategic challenges.
- • Coultreon's rebranding signals a transition from asset-rescue vehicle to fully independent biopharmaceutical company with standalone market identity and growth trajectory.
- • The transaction demonstrates continued M&A activity in biotech, where acquisition of undervalued or orphaned drug assets remains a viable path to value creation for specialized investors.
Summary
Onco3R Therapeutics, a Belgian biotech company established in 2025 as a specialized acquirer of distressed assets from Galapagos Pharmaceuticals, has announced a $125 million Series A funding round and a corporate rebrand to Coultreon Biopharma. The funding round represents validation of the company's strategy to rescue drug candidates and development programs that were either deprioritized or divested by Galapagos, positioning them as the foundation for an independent development platform.
The company's founding model reflects a broader trend in biotech M&A where smaller, focused entities acquire orphaned assets from larger firms undergoing portfolio rationalization or financial restructuring. By acquiring these candidates at favorable valuations, Coultreon gains access to intellectual property and clinical data at a lower cost than de novo development would require. The rebranding from Onco3R to Coultreon Biopharma signals the company's evolution beyond a mere asset-holding vehicle into a branded, standalone biopharmaceutical company with its own strategic identity and commercial trajectory.
The $125 million Series A provides substantial capital to advance the rescued Galapagos candidates through clinical development and toward commercialization. For institutional investors and alternative investment professionals, this deal exemplifies a recurring pattern in biotech: large-cap companies divest programs that don't align with strategic priorities, creating opportunities for specialized investors to acquire valuable assets at discount valuations and generate returns through subsequent development and exits.
The company's founding model reflects a broader trend in biotech M&A where smaller, focused entities acquire orphaned assets from larger firms undergoing portfolio rationalization or financial restructuring. By acquiring these candidates at favorable valuations, Coultreon gains access to intellectual property and clinical data at a lower cost than de novo development would require. The rebranding from Onco3R to Coultreon Biopharma signals the company's evolution beyond a mere asset-holding vehicle into a branded, standalone biopharmaceutical company with its own strategic identity and commercial trajectory.
The $125 million Series A provides substantial capital to advance the rescued Galapagos candidates through clinical development and toward commercialization. For institutional investors and alternative investment professionals, this deal exemplifies a recurring pattern in biotech: large-cap companies divest programs that don't align with strategic priorities, creating opportunities for specialized investors to acquire valuable assets at discount valuations and generate returns through subsequent development and exits.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.